ILMN - Illumina - Stock Forecast

Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

ILMN is currently covered by 18 analysts with an average price target of $197.67. This is a potential downside of $71.75 (-26.63%) from yesterday's end of day stock price of $269.42.

Illumina's activity chart (see below) currently has 737 price targets and 537 ratings on display. The stock rating distribution of ILMN is 36.36% HOLD, 14.55% SELL and 49.09% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 84.11% with an average time for these price targets to be met of 293.49 days.

Highest price target for ILMN is $310, Lowest price target is $95, average price target is $197.67.

Most recent stock forecast was given by MASON CARRICO from STEPHENS. First documented stock forecast 03-Jan-2013.

Overview

Illumina is a life science tools and integrated systems company that focuses on large-scale analysis of genetic variation and function. The company operates through two segments, Core Illumina and GRAIl:

  • The Core Illumina segment develops and markets genomic analysis products and services. This segment’s products are used for applications such as cancer research, reproductive and genetic health, and agriculture.
  • The GRAIL segment focuses on developing multi-cancer early detection tests using Illumina’s sequencing technology. The GRAIL segment aims to develop blood tests that can detect multiple types of cancer at an early stage.

The company’s Galleri test is a multi-cancer early detection test that can detect more than 50 types of cancer through a simple blood draw.

In addition to its products, Illumina provides a range of services including whole-genome sequencing, genotyping, non-invasive prenatal testing (NIPT), and product support services.

History

Illumina was incorporated in 1998 and is headquartered in San Diego, California.

Currently out of the existing stock ratings of ILMN, 20 are a HOLD (36.36%), 8 are a SELL (14.55%), 27 are a BUY (49.09%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 13-Dec-2023

$275

$5.58 (2.07%)

$110

Hold Since 11-Jan-2024

$300

$30.58 (11.35%)

$190

7 days ago
(18-Oct-2026)

24/36 (66.67%)

$37.34 (14.22%)

324

Sell Since 03-Mar-2025

$200

$-69.42 (-25.77%)

$160

19 days ago
(06-Oct-2026)

23/32 (71.88%)

$-67.76 (-25.31%)

147

Buy Since 14-May-2026

$310

$40.58 (15.06%)

$230

21 days ago
(04-Oct-2026)

22/23 (95.65%)

$16.31 (5.55%)

149

Buy Since 13-Dec-2023

$305

$35.58 (13.21%)

$226

25 days ago
(30-Sep-2026)

8/9 (88.89%)

$39.28 (14.78%)

132

Show more analysts

Please expand the browser size to see the chart

What is ILMN (Illumina) average time for price targets to be met?

On average it took 293 days for the stock forecasts to be reached, with an average price target met ratio of 84.11%.

Which analyst most recently updated their price target on ILMN (Illumina)?

Mason Carrico

Which analyst has the most public recommendations on ILMN (Illumina)?

Mason Carrico works at STEPHENS and has 4 price targets and 7 ratings on ILMN

Which analyst is the currently most bullish on ILMN (Illumina)?

Steven Mah with the highest potential upside of $275.33

Which analyst is the currently most reserved on ILMN (Illumina)?

Patrick Donnelly with the lowest potential downside of -$174.42
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?